Cue Biopharma, Inc , a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders.
infoCue Biopharma is a micro cap stock with a total market cap of 138.03M.
infoThey trade on the NASDAQ and had their IPO 5 years and 7 months ago.
infoCue Biopharma currently employs 51 people.
infoAs of Wednesday, Aug 23 2023, Cue Biopharma’s share price is $3.07.
News Relating to Cue Biopharma
Seeking Alpha
Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript
Wednesday Aug 09 2023 at 22:23
Cue Biopharma, Inc. (NASDAQ:CUE ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Dan Passeri – Chief Executive Officer Anish Suri – President & Chief Scientific Officer Matteo Levisetti – Chief Medical Officer Kerri Millar – Chief Financial Officer Conference Call Participants Ted Tenthoff – Piper Sandler Ren Benjamin – JMP Securities Operator Greetings, and welcome to the Cue Biopharma Investor Update Call. At this time, all participants are in a listen-only mode.
InvestorPlace
3 Biotech Stocks to Buy as Companies Ink Major Deals
Thursday Jun 22 2023 at 06:40
With patent expirations around the corner, some of the biggest pharmaceutical and biotech companies will soon face generic competition, creating a big opportunity for these top biotech stocks to buy. In 2023 alone, pharmaceutical and biotech companies spent about $85 billion on acquisitions.
GlobeNewsWire
Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
Monday Jun 05 2023 at 08:00
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that it will present at the Jefferies Global Healthcare Conference being held June 7–9, 2023 in New York.
InvestorPlace
3 Biotech Stocks Sitting on Huge-Upside Catalysts
Friday May 26 2023 at 06:19
Now is a great time to start accumulating top biotech stocks. The biotech boom is red-hot.
GlobeNewsWire
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
Monday May 08 2023 at 08:00
BOSTON, May 08, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held at the New York Hilton Midtown, May 15-16, 2023.
InvestorPlace
7 High-Potential Penny Stocks in the Biotech Sector
Thursday May 04 2023 at 13:56
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ: AXSM ), for example.
Seeking Alpha
Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript
Tuesday Mar 21 2023 at 23:00
Cue Biopharma, Inc. (NASDAQ:CUE ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Dan Passeri – CEO Matteo Levisetti – Chief Medical Officer Ken Pienta – Clinical Advisory Anish Suri – President and Chief Scientific Officer Kerri Millar – CFO Sara Pai – Surgical Oncologist and Director, Translational Head and Neck Cancer Research, Mass General Hospital Conference Call Participants Ted Tenthoff – Piper Sandler Ren Benjamin – JMP Securities Mark Breidenbach – Oppenheimer Stephen Willey – Stifel Operator Greetings, and welcome to the Cue Biopharma Fourth Quarter and Full Year 2022 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.
GlobeNewsWire
Cue Biopharma to Host Business Update Call and Webcast
Wednesday Mar 15 2023 at 08:00
BOSTON, March 15, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that it will host a conference call and webcast to provide a business and clinical update on Tuesday, March 21, 2023 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s website.
GlobeNewsWire
Cue Biopharma to Present at Two February 2023 Scientific Conferences
Wednesday Feb 01 2023 at 08:00
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that its President and Chief Scientific Officer, Anish Suri, Ph.D., will participate in two scientific conferences this February, the Immuno-Oncology 360 o Summit, taking place February 7-10 in New York, NY, and the Federation of American Societies for Experimental Biology (FASEB) Catalyst Conference, taking place virtually February 8-9, 2023.
Seeking Alpha
Cue Biopharma, Inc. (CUE) Q3 2022 Earnings Call Transcript
Monday Nov 14 2022 at 23:23
Cue Biopharma, Inc. (NASDAQ:CUE ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Dan Passeri – Chief Executive Officer Anish Suri – President & Chief Scientific Officer Ken Pienta – Acting Chief Medical Officer Matteo Levisetti – Senior Vice President of Clinical Development Kerri Millar – Chief Financial Officer Conference Call Participants Reni Benjamin – JMP Securities Operator Greetings, and welcome to the Cue Biopharma Update Call. A question-and-answer session will follow the presentation.
GlobeNewsWire
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
Wednesday Nov 09 2022 at 08:00
BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today that it will present at two investor conferences this November, the Stifel Healthcare Conference 2022, to be held November 15-16 in New York, and the Jefferies London Healthcare Conference, to be held in London, UK, November 15-17.
GlobeNewsWire
Cue Biopharma to Host Business Update Call and Webcast
Monday Nov 07 2022 at 08:00
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today that it will host a conference call and webcast to provide a business update on Monday, November 14, 2022 at 4:30 p.m. EST. Live and archived versions of the event can be accessed via the Company’s website.
Seeking Alpha
Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2022 Results – Earnings Call Transcript
Tuesday Aug 23 2022 at 20:13
Cue Biopharma, Inc. (NASDAQ:CUE ) Q2 2022 Earnings Conference Call August 23, 2022 4:30 PM ET Company Participants Dan Passeri – Chief Executive Officer Anish Suri – President & Chief Scientific Officer Ken Pienta – Acting Chief Medical Officer Matteo Levisetti – SVP, Clinical Development Kerri Millar – Chief Financial Officer Conference Call Participants Stephen Wiley – Stifel Reni Benjamin – JMP Securities Mark Breidenbach – Oppenheimer Operator Greetings and welcome to the Cue Biopharma Update Call. At this time, all participants are in a listen-only mode.
Zacks Investment Research
Here’s Why Cue Biopharma, Inc. (CUE) Looks Ripe for Bottom Fishing
Tuesday Aug 23 2022 at 11:18
Cue Biopharma, Inc. (CUE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock’s potential for a turnaround in the near term.
GlobeNewsWire
Cue Biopharma to Present at the Guggenheim I&I Spotlight Series
Monday Jul 11 2022 at 08:00
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today that it will take part in a fireside chat at the Guggenheim I&I Spotlight Series – Treg-based Therapies being held July 12–13, 2022.
GlobeNewsWire
Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Thursday May 26 2022 at 17:00
BOSTON, May 26, 2022 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will give a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held in-person June 3–7 at the McCormick Place Convention Center in Chicago, Illinois and virtually.
Zacks Investment Research
Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 6.4% Jump Turn into More Strength?
Monday Apr 04 2022 at 10:33
Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn’t suggest further strength down the road.
Zacks Investment Research
Cue Biopharma, Inc. (CUE) Stock Jumps 6.5%: Will It Continue to Soar?
Tuesday Feb 15 2022 at 10:04
Cue Biopharma, Inc. (CUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks Investment Research
Cue Biopharma, Inc. (CUE) Soars 8.3%: Is Further Upside Left in the Stock?
Thursday Jan 27 2022 at 06:55
Cue Biopharma, Inc. (CUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
GlobeNewsWire
Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials
Thursday Jan 20 2022 at 08:00
CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will host a conference call and webcast to provide a clinical update on Wednesday, January 26, 2022 at 4:30 p.m. EST. Live and archived versions of the event can be accessed via the Company’s website.
GlobeNewsWire
Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference
Monday Nov 22 2021 at 08:00
CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that it participated in a pre-recorded fireside chat as part of the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held on November 29-December 2, 2021.
GlobeNewsWire
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
Wednesday Nov 10 2021 at 08:00
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will take part in two fireside chats, the first at the Stifel Healthcare Conference 2021, November 15-17, and the second at the Jefferies London Healthcare Conference, November 16-19. Both conferences will be held virtually.
Zacks Investment Research
Analysts Estimate Cue Biopharma, Inc. (CUE) to Report a Decline in Earnings: What to Look Out for
Tuesday Nov 09 2021 at 16:02
Cue Biopharma, Inc. (CUE) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewsWire
Cue Biopharma Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101
Tuesday Sep 21 2021 at 08:00
Patents Further Strengthen and Enhance Intellectual Property (IP) Portfolio Patents Further Strengthen and Enhance Intellectual Property (IP) Portfolio
Seeking Alpha
Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2021 Results – Earnings Call Transcript
Tuesday Aug 17 2021 at 21:40
Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2021 Results – Earnings Call Transcript
GlobeNewsWire
Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and Business Highlights
Tuesday Aug 17 2021 at 16:01
CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, provided a business and clinical progress update for the second quarter 2021.
GlobeNewsWire
Cue Biopharma to Host Business Update Call and Webcast
Tuesday Aug 10 2021 at 08:00
CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will host a conference call and webcast to provide a business update on Tuesday, August 17, 2021 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s website.
GlobeNewsWire
Cue Biopharma to Present Corporate Update at the Upcoming BTIG Virtual Biotechnology Conference
Tuesday Aug 03 2021 at 08:00
CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will participate in a fireside chat at the BTIG Virtual Biotechnology Conference being held August 9-10 2021.
Zacks Investment Research
Earnings Preview: Cue Biopharma, Inc. (CUE) Q2 Earnings Expected to Decline
Friday Jul 30 2021 at 16:43
Cue Biopharma, Inc. (CUE) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewsWire
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
Monday Jun 14 2021 at 08:00
CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held June 16-17, 2021.
Cue Biopharma Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Cue Biopharma’s Altman Z-score is -3.87 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Cue Biopharma Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has bought $8.58K of common stock in Cue Biopharma on the stock market with no insider selling.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Cue Biopharma’s Income Quality of 0.75 is in line with its Industry Group of 0.69 (8.7% greater)
Cue Biopharma’s Income Quality of 0.75 is in line with its Major Industry Group of 0.71 (5.6% greater)
Cue Biopharma’s Income Quality of 0.75 is in line with its Sector of 0.75
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Cue Biopharma’s Current Ratio of 3.74 is lower than its Industry Group of 4.76 (-21.4% lower)
Cue Biopharma’s Current Ratio of 3.74 is lower than its Major Industry Group of 4.32 (-13.4% lower)
Cue Biopharma’s Current Ratio of 3.74 is greater than its Sector of 2.6 (43.8% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-2.67 & -1.27)
Cannot compare a negative PE Ratio (-2.67 & -1.1)
Cannot compare a negative PE Ratio (-2.67 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Cue Biopharma’s PB Ratio of 3.0 is greater than its Industry Group of 1.34 (123.9% greater)
Cue Biopharma’s PB Ratio of 3.0 is greater than its Major Industry Group of 1.4 (114.3% greater)
Cue Biopharma’s PB Ratio of 3.0 is greater than its Sector of 1.62 (85.2% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Cue Biopharma’s ROE of -1.12 is lower than its Industry Group of -0.44 (-154.5% lower)
Cue Biopharma’s ROE of -1.12 is lower than its Major Industry Group of -0.38 (-194.7% lower)
Cue Biopharma’s ROE of -1.12 is lower than its Sector of -0.03 (-3633.3% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Cue Biopharma’s ROCE of -0.93 is lower than its Industry Group of -0.42 (-121.4% lower)
Cue Biopharma’s ROCE of -0.93 is lower than its Major Industry Group of -0.37 (-151.4% lower)
Cue Biopharma’s ROCE of -0.93 is lower than its Sector of -0.04 (-2225.0% lower)
Derived from SEC.GOV filing dataopen_in_new